Another strategy makes use of ZFNs to disrupt the GATA1 binding site of the +58 erythroid-specific enhancer of BCL11A in cells from SCD and β-thalassemia patients (clinical trials NCT03653247 and NCT03432364, respectively) (Table 2). The gene discussed is BCL11A; the disease is Schnyder corneal dystrophy.